 CAMBRIDGE, Mass.--BUSINESS WIRE--Alnylam Pharmaceuticals, Inc. Nasdaq: ALNY, the leading RNAi therapeutics company, today announced full positive results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated ATTR amyloidosis, which met its primary and both secondary endpoints at nine months in patients with hereditary ATTR hATTR amyloidosis with polyneuropathy. The results were presented today in an 